{
    "clinical_study": {
        "@rank": "134303", 
        "arm_group": [
            {
                "arm_group_label": "H0E901-U300 Morning then Evening", 
                "arm_group_type": "Experimental", 
                "description": "Treatment period A (8 weeks): morning injection followed by Treatment period B (8 weeks): evening injection"
            }, 
            {
                "arm_group_label": "Lantus Morning then Evening", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "HOE901-U300 Evening then Morning", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Lantus Evening then Morning", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      - To compare the glucose control during treatment with a new formulation of insulin glargine\n      and Lantus in adult patients with type 1 diabetes mellitus\n\n      Secondary Objectives:\n\n        -  To compare a new formulation of insulin glargine and Lantus given in the morning or in\n           the evening\n\n        -  To compare the incidence and frequency of hypoglycemic episodes\n\n        -  To assess the safety and tolerability of the new formulation of insulin glargine"
        }, 
        "brief_title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Up to 4-week screening period;\n\n        -  16-week open-label comparative efficacy and safety treatment period;\n\n        -  4-week post-treatment safety follow-up period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Patients with type 1 diabetes mellitus\n\n        Exclusion criteria:\n\n          -  HbA1c >9% (at screening);\n\n          -  Patients receiving >0.5 U/kg body weight basal insulin in the last 30 days prior to\n             screening visit;\n\n          -  Patients not on stable insulin dose (\u00b120% total basal insulin dose) in the last 30\n             days prior to screening visit;\n\n          -  Less than 1 year on any basal plus mealtime insulin;\n\n          -  Patients using pre-mix insulins, human regular insulin as mealtime insulin and/or any\n             antidiabetic drugs other than basal insulin and mealtime analogue insulin in the last\n             3 months before screening visit;\n\n          -  Use of an insulin pump in the last 6 months before screening visit;\n\n          -  Any contraindication to use of insulin glargine as defined in the national product\n             label;\n\n          -  Not willing to inject insulin glargine as assigned by the randomization process once\n             daily in the morning or evening;\n\n          -  Hospitalization for diabetic ketoacidosis or history of severe hypoglycemia\n             (requiring 3rd party assistance) in the last 6 months prior to randomization;\n\n          -  Initiation of any glucose-lowering agents in the last 3 months before screening\n             visit;\n\n          -  Weight change of \u22655 kg during the last 3 months prior to screening visit;\n\n          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic\n             retinopathy or macular edema likely to require laser, surgical treatment or\n             injectable drugs during the study period;\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658579", 
            "org_study_id": "PDY12777", 
            "secondary_id": "U1111-1130-3593"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "H0E901-U300 Morning then Evening", 
                    "HOE901-U300 Evening then Morning"
                ], 
                "description": "Pharmaceutical form: solution\nRoute of administration: subcutaneous", 
                "intervention_name": "HOE901-U300 (new formulation of insulin glargine)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Lantus Morning then Evening", 
                    "Lantus Evening then Morning"
                ], 
                "description": "Pharmaceutical form: solution\nRoute of administration: subcutaneous", 
                "intervention_name": "Lantus (insulin glargine)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Temecula", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92591"
                    }, 
                    "name": "Investigational Site Number 840002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55416"
                    }, 
                    "name": "Investigational Site Number 840001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97201-3098"
                    }, 
                    "name": "Investigational Site Number 840003"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A 16-week, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine Versus Lantus in Patients With Type 1 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percent (%) of time in target plasma glucose range (80-140mg/dL)", 
            "safety_issue": "No", 
            "time_frame": "up to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent time above the upper limit (> 140 mg/dL; i.e. > 7.8 mmol/L) of glycemic range", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "Percent time below the lower limit (< 80 mg/dL; i.e. < 4.4 mmol/L) of glycemic range", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "Evaluation of diurnal glucose exposure, variability, and stability", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "Average time within glycemic range >80 mg/dL (4.4 mmol/L) and \u2264140 mg/dL (7.8 mmol/L) in the last four hours of each dosing interval", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 weeks"
            }, 
            {
                "measure": "Change in HbA1c from baseline to endpoint", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 16 weeks"
            }, 
            {
                "measure": "Change in fasting plasma glucose (FPG) from baseline to endpoint", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 16 weeks"
            }, 
            {
                "measure": "Change in 7-point self-monitored plasma glucose (SMPG) per timepoint from baseline to endpoint", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 16 week"
            }, 
            {
                "measure": "Change in daily basal insulin dose from baseline to endpoint", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 16 week"
            }, 
            {
                "measure": "Number of Patients with various types of Hypoglycemia Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}